comparemela.com

Latest Breaking News On - Dunedin enterprise investment trust - Page 13 : comparemela.com

TRADING UPDATES: Ocean Wilsons annual profit slips; dividend unchanged

TRADING UPDATES: Ocean Wilsons annual profit slips; dividend unchanged Mon, 15th Mar 2021 19:07 (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Ocean Wilsons Holdings Ltd - Bermuda-based investment company operating a maritime services company in Brazil - Posts pretax profit for 2020 of USD74.6 million, slipping 9.6% from USD82.5 million the year prior. Revenue decreases 13% to USD352.8 million from USD406.1 million. Proposed dividend of 70 US cents per share, unchanged from year prior. Says 2021 is looking more optimistic as the vaccine roll-out programme starts in earnest, and the blend of better growth together with still abundant liquidity should serve to underpin risk assets. Says it sees little reason to deviate from its positive stance on equities and more cautious view on bonds.

LONDON TRADING UPDATES: Motif Bio Says Orange Avenue Buys Subsidiary

LONDON TRADING UPDATES: Motif Bio Says Orange Avenue Buys Subsidiary Fri, 26th Feb 2021 20:20 (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Motif Bio PLC - AIM-listed cash shell - Enters into a stock purchase agreement with Orange Avenue Technologies LLC, to which Orange has acquired 100% of the outstanding shares of Motif Inc from Motif with immediate effect. Orange is wholly owned by John Palmer, president of Tamarack Associates Inc - the company which was engaged by Motif to facilitate the sale of iclaprim and other assets of Motif Inc in January 2020. Motif remains suspended from trading while the proposed transaction is being negotiated and advanced. The transaction is an important step to prepare Motif to complete the reverse takeover. It also creates incentives for Orange to focus on the potential generation of value from iclaprim for Motif s shareholders, while allowing M

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.